LGI1 and viral encephalitis: The prominent clinical feature of anti-LGI1 encephalitis is drug-resistant epilepsy, but most patients respond well to first-line immunotherapy plus anti-epileptic drugs (AEDs) and can gradually discontinue medication after their condition has been relieved (1, 2).